Treats acute decompensated heart failure. ANDA 209666, held by Eugia Pharma. Milrinone Lactate.
As of Nov 16, 2026, ANDA 209666 (Milrinone Lactate In Dextrose 5%), held by Eugia Pharma, was first approved by FDA on Sep 3, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Milrinone Lactate in 5% Dextrose Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 3, 2020 | Original application | Approved | None posted |
| Milrinone Lactate In Dextrose 5%EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) · injectable;injection | Milrinone Lactate | Rx |
| Milrinone Lactate In Dextrose 5%EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) · injectable;injection | Milrinone Lactate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters